Updates are available Correction dated 2026-01-13
Click to view Correction: https://doi.org/10.1038/s41590-026-02420-x
-
Authors
Park, Simone L. https://orcid.org/0000-0003-1507-0864
Painter, Mark M. https://orcid.org/0000-0002-0180-2748
Manne, Sasikanth
Alcalde, Victor
McLaughlin, Maura
Sullivan, Matthew A. https://orcid.org/0000-0003-3651-0478
Mathew, Divij https://orcid.org/0000-0002-8323-7358
Torres, Leonel
Huang, Yinghui J. https://orcid.org/0000-0003-0974-9539
Reeg, David B. https://orcid.org/0009-0000-8179-1833
Douek, Naomi R.
Campos, Trenton
Klapholz, Max https://orcid.org/0000-0001-6527-8722
Cardenas, Maria A.
Fang, Victoria
Ngiow, Shin Foong
KC, Wumesh
Goel, Rishi R.
Baxter, Amy E.
Wu, Jennifer E.
Tan, Melody
Berry, Corbett T. https://orcid.org/0000-0001-9348-2034
Ellebrecht, Christoph T. https://orcid.org/0000-0001-7656-0491
Huang, Alexander C. https://orcid.org/0000-0002-0099-0492
Papazian, Emily
Liu, Ying https://orcid.org/0000-0003-0165-8157
Rajasekaran, Karthik
Brody, Robert M.
Thaler, Erica R.
Basu, Devraj
Diab, Ahmed https://orcid.org/0000-0001-6626-7013
Giles, Josephine R.
Wherry, E. John https://orcid.org/0000-0003-0477-1956
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 21 October 2025
First Online: 29 December 2025
Change Date: 13 January 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-026-02420-x
Competing interests
: A.C.H. received research funding from Bristol Myers Squibb and Merck. C.T.E. holds equity in Cabaletta Bio and has licensed patents with Cabaletta Bio and Novartis. J.R.G. is a consultant for Arsenal Biosciences, Cellanome, Seismic Therapeutics and GVM1. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy which supported this study. E.J.W. is an advisor for Arpelos Bioscience, Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, New Limit, Marengo, Pluto Immunotherapeutics, Related Sciences, Santa Ana Bio and Synthekine. E.J.W. is a founder of Arpelos Bioscience, Danger Bio and Arsenal Biosciences. E.J.W. holds stock in Coherus. The other authors declare no competing interests.
